Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide
2. Surufatinib
1. 1308672-74-3
2. Surufatinib
3. N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide
4. Hmpl-012
5. Kdr-in-1
6. 1816307-67-1
7. Hmpl012
8. Surufatinib [inn]
9. Surufatinib [usan]
10. B2k5l1l8s9
11. N-[2-(dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1h-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide
12. Benzenemethanesulfonamide, N-(2-(dimethylamino)ethyl)-3-((4-((2-methyl-1h-indol-5-yl)oxy)-2-pyrimidinyl)amino)-
13. Benzenemethanesulfonamide, N-[2-(dimethylamino)ethyl]-3-[[4-[(2-methyl-1h-indol-5-yl)oxy]-2-pyrimidinyl]amino]-
14. Sulanda
15. N-[2-(dimethylamino)ethyl]-1-[3-({4-[(2-methyl-1h-indol-5-yl)oxy]pyrimidin-2-yl}amino)phenyl]methanesulfonamide
16. Sulfatinib [who-dd]
17. Sulfatinib; Hmpl-012
18. Unii-b2k5l1l8s9
19. Surufatinib [who-dd]
20. Gtpl9769
21. Schembl1822601
22. Chembl4297190
23. Bcp14757
24. Ex-a2524
25. Nsc797937
26. Who 10349
27. Akos030632837
28. Zinc117218067
29. Cs-5949
30. Db15106
31. Nsc-797937
32. Ac-35852
33. As-74954
34. Hmpl-012;hmpl 012;hmpl012
35. Hy-12297
36. Vegfr2 Inhibitor [wo2011060746]
37. D71057
38. A926546
39. N-(2-(dimethylamino) Ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide
40. N-(2-(dimethylamino) Ethyl)-1-(3-((4-(2-methyl-1h-indol-5-yloxy) Pyrimidin-2-yl) Amino) Phenyl) Methanesulfonamide
| Molecular Weight | 480.6 g/mol |
|---|---|
| Molecular Formula | C24H28N6O3S |
| XLogP3 | 3.4 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 10 |
| Exact Mass | 480.19435995 g/mol |
| Monoisotopic Mass | 480.19435995 g/mol |
| Topological Polar Surface Area | 121 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 733 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms), Treatment of malignant neoplasms of haematopoietic and lymphoid tissue
Drugs in Development
Details:
Hutchmed will initiate a clinical advancement of their lead product Sulanda (surufatinib) in combination with camrelizumab for the treatment of naïve pancreatic ductal adenocarcinoma.
Lead Product(s): Surufatinib,Camrelizumab
Therapeutic Area: Oncology Brand Name: Sulanda
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: HengRui
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 15, 2024
Lead Product(s) : Surufatinib,Camrelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : HengRui
Deal Size : Undisclosed
Deal Type : Collaboration
HUTCHMED Initiates Phase II/III Trial of Surufatinib & Camrelizumab for Pancreatic Cancer
Details : Hutchmed will initiate a clinical advancement of their lead product Sulanda (surufatinib) in combination with camrelizumab for the treatment of naïve pancreatic ductal adenocarcinoma.
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 15, 2024
Details:
Safety and efficacy of HMPL-012 (surufatinib), an oral inhibitor of angiogenesis and immune modulation, was demonstrated in SANET-p and SANET-ep studies, in patients with advanced pNETs and epNETs conducted in China.
Lead Product(s): Surufatinib
Therapeutic Area: Oncology Brand Name: Sulanda
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 05, 2022
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Safety and efficacy of HMPL-012 (surufatinib), an oral inhibitor of angiogenesis and immune modulation, was demonstrated in SANET-p and SANET-ep studies, in patients with advanced pNETs and epNETs conducted in China.
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 05, 2022
Details:
Sulanda (Surufatinib), a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptors and fibroblast growth factor receptor.
Lead Product(s): Surufatinib,Etoposide,Toripalimab
Therapeutic Area: Oncology Brand Name: Sulanda
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 12, 2021
Lead Product(s) : Surufatinib,Etoposide,Toripalimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sulanda (Surufatinib), a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptors and fibroblast growth factor receptor.
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 12, 2021
Details:
SURTORI-01, a Phase III study to evaluate the efficacy and safety of surufatinib (SULANDA), a novel, oral angio-immuno kinase inhibitor in combination with toripalimab compared with FOLFIRI to treat patients with advanced neuroendocrine carcinoma.
Lead Product(s): Surufatinib,Toripalimab
Therapeutic Area: Oncology Brand Name: Sulanda
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 21, 2021
Lead Product(s) : Surufatinib,Toripalimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the T...
Details : SURTORI-01, a Phase III study to evaluate the efficacy and safety of surufatinib (SULANDA), a novel, oral angio-immuno kinase inhibitor in combination with toripalimab compared with FOLFIRI to treat patients with advanced neuroendocrine carcinoma.
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2021
Details:
This trial is to explore potential synergistic activity of the novel, oral angio-immuno kinase inhibitor surufatinib with the anti-PD-1 antibody tislelizumab in enhancing overall antitumor activity from inhibition of angiogenesis along with stimulation of an immune response.
Lead Product(s): Surufatinib,Tislelizumab
Therapeutic Area: Oncology Brand Name: Sulanda
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 24, 2021
Lead Product(s) : Surufatinib,Tislelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This trial is to explore potential synergistic activity of the novel, oral angio-immuno kinase inhibitor surufatinib with the anti-PD-1 antibody tislelizumab in enhancing overall antitumor activity from inhibition of angiogenesis along with stimulation o...
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 24, 2021
Details:
Surufatinib received fast track designation in April 2020 for the treatment of pancreatic and extra-pancreatic NET. Orphan Drug Designation for pancreatic NET was also granted in November 2019.
Lead Product(s): Surufatinib
Therapeutic Area: Oncology Brand Name: Sulanda
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 07, 2021
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroend...
Details : Surufatinib received fast track designation in April 2020 for the treatment of pancreatic and extra-pancreatic NET. Orphan Drug Designation for pancreatic NET was also granted in November 2019.
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2021
Details:
The NMPA approval of Sulanda® was based on results from the SANET-ep study. The Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS in all subgroups of non-pancreatic NET patients with an acceptable risk/benefit ratio.
Lead Product(s): Surufatinib
Therapeutic Area: Oncology Brand Name: Sulanda
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 30, 2020
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroen...
Details : The NMPA approval of Sulanda® was based on results from the SANET-ep study. The Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS in all subgroups of non-pancreatic NET patients with an acceptab...
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 30, 2020
Details:
The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acceptable risk/benefit ratio.
Lead Product(s): Surufatinib
Therapeutic Area: Oncology Brand Name: Sulanda
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 28, 2020
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acceptable risk/benefit ratio.
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 28, 2020
Details:
Application is based on the scientific advice which the company got from the European Medicines Agency’s Committee for Medicinal Products for Human Use for surufatinib for the treatment of patients with advanced neuroendocrine tumors.
Lead Product(s): Surufatinib
Therapeutic Area: Oncology Brand Name: Sulanda
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 08, 2020
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Application is based on the scientific advice which the company got from the European Medicines Agency’s Committee for Medicinal Products for Human Use for surufatinib for the treatment of patients with advanced neuroendocrine tumors.
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 08, 2020
Details:
Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”).
Lead Product(s): Surufatinib
Therapeutic Area: Oncology Brand Name: Sulanda
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 20, 2020
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”).
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
CAS Number : 3934-20-1
End Use API : Surufatinib
About The Company : Suraj Laboratories Private Limited, established in 2021, is a pharmaceutical firm providing Contract Research and Manufacturing Services (CRAMS), Custom Synthes...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
17
PharmaCompass offers a list of Surufatinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Surufatinib manufacturer or Surufatinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Surufatinib manufacturer or Surufatinib supplier.
PharmaCompass also assists you with knowing the Surufatinib API Price utilized in the formulation of products. Surufatinib API Price is not always fixed or binding as the Surufatinib Price is obtained through a variety of data sources. The Surufatinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Surufatinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Surufatinib, including repackagers and relabelers. The FDA regulates Surufatinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Surufatinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Surufatinib supplier is an individual or a company that provides Surufatinib active pharmaceutical ingredient (API) or Surufatinib finished formulations upon request. The Surufatinib suppliers may include Surufatinib API manufacturers, exporters, distributors and traders.
Surufatinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Surufatinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Surufatinib GMP manufacturer or Surufatinib GMP API supplier for your needs.
A Surufatinib CoA (Certificate of Analysis) is a formal document that attests to Surufatinib's compliance with Surufatinib specifications and serves as a tool for batch-level quality control.
Surufatinib CoA mostly includes findings from lab analyses of a specific batch. For each Surufatinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Surufatinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Surufatinib EP), Surufatinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Surufatinib USP).
